Cedarburg Pharmaceuticals has acquired InB: Hauser Pharmaceutical Services. The acquisition is intended to strengthen Cedarburg’s position in the rapidly growing CDMO market and “leverage the trusted reputation and synergistic capabilities of both companies to offer clients a more fully-integrated manufacturing platform strategically focused on helping client’s move NCEs to market,” according to a Cedarburg statement.

Hauser’s expertise in natural products, isolation / purification and cGMP manufacturing augment Cedarburg’s synthetic chemistry and cGMP manufacturing expertise and effectively broadens the overall service capabilities offered to clients. The acquisition expands Cedarburg’s extensive inventory of unit operations and comprehensive analytical instrumentation to include NMR and MALS and further amplifies Cedarburg’s toll manufacturing capabilities for the production of APIs and key intermediates.

The newly formed company, called Cedarburg Hauser Pharmaceuticals, Inc., will offer customers a broad range of best-in-class pharmaceutical services to meet the development and production needs of its clients. The companies offer a combined 34-year history working in the pharmaceutical industry, and will offer more than 70,000 sq. ft. of multi-purpose U.S.-based FDA-registered facilities with process development laboratories, kilo and commercial scale manufacturing suites, analytical and microbiology laboratories, stability and material sample storage.